According to Biosimilars Forum, the biosimilar market is one of the most dynamic and transformative opportunities in healthcare today, driving cost savings of up to 85% and expanding access to life-changing biologic therapies. But let’s face it—commercializing and launching a biosimilar is no easy feat. It requires a strategic approach to commercialization, deep market expertise, and, most importantly, the right sales team to execute flawlessly. That’s where Amplity’s outsourced pharma sales and sales enablement teams for biosimilars come in. With a proven track record and unmatched expertise, Amplity is the trusted partner pharmaceutical manufacturers rely on to navigate the complexities of biosimilar commercialization and develop dynamic and effective US commercial deployment strategies.
The numbers don’t lie. Since 2015, over 75 biosimilars for 20 reference biologics have been approved in the U.S., with more than 50 of those launched commercially. Despite this progress, biosimilars still account for just 2–3% of the biologics market. The reason? Launching a biosimilar isn’t the same as introducing a generic drug. Biosimilars require a much deeper understanding of scientific data, regulatory requirements, and physician education. Add to that the need to build trust with HCPs who may be hesitant to switch from a reference biologic, and you’ve got quite the uphill battle.
As Brian O’Donnell, President of Contract Sales Teams at Amplity, explains: “You’re not selling increased efficacy or fewer side effects. You’re selling the idea that this product has no clinical meaningful differences to the originator. It’s a unique challenge that requires a skilled team capable of building trust, educating stakeholders, and addressing concerns.”
Beyond convincing providers of biosimilars’ clinical comparability, manufacturers must also navigate hurdles like patent thickets, exclusivity strategies, and the financial complexities of the medical benefit/“buy-and-bill” and pharmacy benefit models. Add regulatory shifts and competitive pressures, and it’s clear why many pharma companies turn to outsourced pharma sales teams for biosimilar launches.
Amplity has been at the forefront of biosimilar launches from the very beginning. In fact, we were the first contract sales organization (CSO) to successfully launch a biosimilar close to 10 years ago. Since then, we’ve set the gold standard for how biosimilars are introduced to the market.
“Our first biosimilar launch started with just 17 sales professionals and one biosimilar,” O’Donnell recalls. “Today, we’ve scaled that team exponentially to meet the growing demand and a portfolio of biosimilars in this space. In fact, every launch we’ve supported has led to team expansions because of the measurable success we’ve delivered.” Recently we have, in some instances, added 505(b)(2) drugs into the biosimilar sales bag.
To date, Amplity has launched over 13 outsourced pharma sales teams for biosimilars across therapeutic areas such as oncology, autoimmune diseases, and rare diseases. And our results speak for themselves, with some clients achieving an ROI of up to 21:1 leveraging our signature blended engagement model.
When it comes to biosimilar commercialization, success hinges on having a sales team that understands the unique challenges and opportunities of this complex market. Amplity’s outsourced sales teams for biosimilars deliver exceptional results by combining several pillars. Here’s what sets us apart:
Biosimilar sales require a consultative and strategic approach, and Amplity’s outsourced sales teams are uniquely equipped to meet this challenge. With deep expertise in biosimilars, biologics, rare diseases, and specialty pharmaceuticals, our teams excel at overcoming the distinct barriers to biosimilar commercialization.
“Our teams are skilled at breaking down misconceptions, addressing hesitations, and advocating for the value of biosimilars. They know how to navigate complex healthcare systems and community-based practices, including buy-and-bill dynamics, to drive adoption,” says Christina DiBiase, Amplity Chief Growth Officer.
To maintain this high level of expertise, Amplity has a robust upskilling infrastructure in place that includes ongoing training and workshops focused on technical knowledge, engagement skills, as well as operational and economic acumen. This ensures that our outsourced biosimilar teams are not only well-prepared but also adaptable to the evolving needs of the market.
“Our teams are not just selling—they’re educating, positioning products, and operationalizing real-world solutions to complex challenges,” adds O’Donnell. This combination of expertise, education, and strategic positioning is what drives success in the biosimilar space.
Biosimilar launches require seamless collaboration across multiple stakeholders within a single account, making coordination essential for success. “You’ll never succeed in biosimilars if you try to do it alone,” says DiBiase. “It’s not just about the healthcare provider. It’s about getting everyone engaged and working together.”
Amplity’s model integrates 3 key roles: sales representatives, who educate and build relationships with HCPs; account directors, who manage contracts and financial discussions; and field reimbursement specialists, who assist with billing, reimbursement, and prior authorization challenges. Together, these teams ensure every stakeholder is aligned. Additionally, Amplity provides additional support like nurse navigators.
“Biosimilar adoption requires coordination across an entire practice,” O’Donnell explains. “We work with everyone—from HCPs, infusion staff and reimbursement teams to pharmacy departments and health system leadership. If even one person isn’t on the same page, it can create barriers. Our teams excel at connecting the dots between all these roles, ensuring smooth collaboration and driving adoption.”
One of the biggest barriers to biosimilar adoption is the lack of understanding among providers, their staff, and payers. Amplity’s outsourced pharma sales teams take on the dual role of educator and advocate to bridge this gap.
“Biosimilars aren’t just sold—they’re championed,” emphasizes Chris Baker, CEO of Amplity. “Driving adoption requires more than promotion; it demands expert collaboration across physicians, pharmacists, and key decision-makers to foster trust and confidence in these therapies.”
This focus on education ensures that stakeholders, including office staff, fully understand the clinical comparability and cost benefits of biosimilars, paving the way for widespread adoption.
In the dynamic biosimilar market, strategies often need to adapt quickly to changing conditions. Amplity’s outsourced sales teams are designed for flexibility, enabling pharma manufacturers to scale efforts as needed to meet their goals.
“This flexibility is especially valuable for biosimilar launches,” says DiBiase. “Whether you need a specialized team or a larger, national presence, Amplity can tailor our approach to meet your specific goals.”
Amplity’s model combines hybrid sales reps, who leverage both in-person and remote touchpoints to maximize engagement, with field-based reps, who build trust through face-to-face relationships. This adaptable approach ensures tailored communication and broad coverage, making it ideal for addressing the complexities of biosimilar launches.
“Our hybrid-field team approach allows us to engage HCPs where and how they prefer, ensuring we deliver the right message at the right time,” DiBiase adds.
Timing is everything in biosimilar launches. Early adoption often determines long-term success, which is why Amplity’s outsourced sales teams are designed for rapid deployment.
“Capturing market share early is critical when competing with established biologics,” says DiBiase. “Our ability to mobilize quickly ensures our clients don’t lose valuable time in a highly competitive market.”
By deploying teams swiftly, Amplity helps pharma manufacturers establish critical relationships with HCPs and maximize early opportunities in key therapeutic areas.
Additionally, we tailor strategies to capture optimal market share based on whether our clients enter the market as first movers or after the initial 3 biosimilars of an originator have been introduced. Speed is key as market conditions and average selling prices (ASP) evolve.
The biosimilar market is on the brink of explosive growth. According to GENerX Life, over the next decade, 118 biologic drugs are expected to lose exclusivity, representing an estimated $230+ billion market opportunity for biosimilars. Regulatory changes, such as the FDA’s proposal to eliminate switching studies for interchangeability designations, are further accelerating adoption. In this fast-moving landscape, having the right partner is crucial. Amplity’s outsourced pharma sales teams for biosimilars ensure that manufacturers are thriving.
When it comes to biosimilar launches, Amplity’s track record is unmatched. “We’ve successfully launched multiple biosimilars, across a broad range of therapeutic areas, and every single one has exceeded expectations,” O’Donnell says. “We know the market, we know how to launch, and we know how to deliver results.”
Amplity’s teams bring industry-leading expertise and a proven track record in launching and accelerating biosimilar uptake. This success stems from deep knowledge of biosimilar market access, strategic recruitment of top-tier talent, and equipping them with compelling messaging for healthcare professionals. “This isn’t about introducing new clinical data,” Baker adds. “It’s about influencing biosimilar utilization through education, awareness, and earned trust.”
Preparing for a biosimilar launch is no small task, so it’s worth asking yourself:
If you’re hesitating to answer “yes” to any of these questions, an outsourced pharma sales team for biosimilars could be the solution you’ve been looking for.
Request a consultation to learn how we can support your next biosimilar launch and set your brand up for long-term success.
